CasNo.74103-07-4,Organic Intermediate Toradol Powder CAS 74103-07-4 Ketorolac Tromethamine / Toradol,Toradol(74103-07-4) Suppliers

0	Negotiable

Min.Order :0
Purity: 99%

Keywords

Toradol 74103-07-4 Ketorolac Tromethamine

Quick Details

Appearance:White powder
Application:Ketorolac is indicated for short-term management of moderate to severe pain. Concerns about the high incidence of reported side effects led to restriction in its dosage and maximum duration of use...
PackAge:Aluminum foil bag,fluorinated bottles,carboard drums or as your special request.
ProductionCapacity:
Storage:Store in cool & dry place. Keep away from strong light Shelf Life2 years when properly stored.
Transportation:1) Door to Door Service by DHL/FEDEX/EMS/TNT for package under 45kgs, about 3~7 days delivery. 2) Port to Port Service by Air for package more than 45kgs, about 3~7 days delivery. 3) Port to Port...

Superiority:

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details:

Ketorolac (tromethamine salt) inhibits both isoforms of Cox in recombinant rat and human enzyme systems. Ketorolac inhibits rat Cox-1 (IC50 of 0.27 μM), rat Cox-2 (IC50 of 2.06 μM), human Cox-1 (IC50 of 1.23 μM) and human Cox-2 (IC50 of 3.50 μM). The (S) enantiomer of Ketorolac with rat Cox-1 (IC50 of 0.10 μM) is approximately twice as potent as the racemate, whereas the (R)-enantiomer (IC50 of > 100 μM) is virtually without activity. Ketorolac shows inhibition of eicosanoid formation in HEL cells (Cox-1, IC50 of 0.025 μM) and LPS-stimulated Mono Mac 6 cells (Cox-2, IC50 of 0.039 μM), but does not significantly inhibit NO accumulation in supernatants of LPS-stimulated RAW 264.7 cells up to 300 μM. Ketorolac significantly inhibits thymidine incorporation of human osteoblasts (hOBs) upon 24 hours treatment in a dose-dependent manner, and inhibits proliferation and arrests cell cycle at G0/G1 phase in hOBs.